Welcome to our dedicated page for CeriBell SEC filings (Ticker: CBLL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
CeriBell, Inc. filings document the regulatory record of a medical technology company commercializing point-of-care EEG systems for neurological monitoring. Its Form 8-K reports include furnished financial results, FDA clearance events for the Clarity seizure-detection algorithm and other Ceribell System indications, and material agreements related to facility leases and headband supply arrangements.
The company’s proxy materials and governance filings cover annual meeting matters, board composition, committee assignments, director compensation arrangements, indemnification agreements, and related shareholder voting procedures. These disclosures provide formal records of Ceribell’s operating updates, governance structure, contractual obligations, and public-company reporting events.
CBLL: A Form 144 notice lists proposed and recent sales of Common stock by an affiliated holder. The filing shows proposed sales of 39,000 shares and earlier transactions including 39,000, 2,084, and 39,000 share entries with cash values recorded. Transactions are labeled as stock option exercises and issuer-related sales.
Ceribell, Inc. reported that President and CEO Chao Xingjuan received equity compensation awards. She was granted a stock option for 162,592 shares of common stock at an exercise price of $18.50 per share, expiring on April 1, 2036, vesting quarterly starting on May 20, 2026. She also received a grant of 97,555 shares of common stock in the form of restricted stock units. Following these awards, she directly holds 864,347 shares of common stock and has an additional 369,088 shares held indirectly through the ACP 2021 Trust, where she is a co-trustee and disclaims beneficial ownership except for her pecuniary interest.
Blumberg Scott reported acquisition or exercise transactions in this Form 4 filing.
Ceribell, Inc. Chief Financial Officer Scott Blumberg reported equity compensation awards. He received a stock option to buy 51,227 shares of common stock at $18.50 per share, expiring on April 1, 2036, and a grant of 30,736 restricted stock units. Following the common stock grant, his direct common stock holdings increased to 149,070 shares. The option shares vest on each quarterly anniversary from May 20, 2026, as long as he remains in an employment or service relationship with Ceribell, making these routine, service-based compensation awards rather than open-market purchases.
Foehr David reported acquisition or exercise transactions in this Form 4 filing.
Ceribell, Inc. senior vice president of finance and principal accounting officer David Foehr reported equity compensation awards. He received a grant of options to buy 36,750 shares of common stock at $18.50 per share, expiring on April 1, 2036, and 22,050 restricted stock units.
The option shares will vest on each quarterly anniversary from May 20, 2026, as long as he continues his service with the company on each vesting date. Following these grants, Foehr directly holds 39,600 shares of common stock. These are compensation-related awards, not open-market purchases or sales.
Manni Joseph S. reported acquisition or exercise transactions in this Form 4 filing.
Ceribell, Inc. reported that Chief Revenue Officer Joseph S. Manni received equity compensation on April 1, 2026. He was granted a stock option to buy 51,227 shares of common stock at $18.50 per share, expiring on April 1, 2036, and a separate grant of 30,736 shares of common stock as restricted stock units. The option vests on each quarterly anniversary from May 20, 2026, subject to his continued service. After these awards, he directly owns 57,669 shares of common stock.
Ceribell, Inc. Chief Technology Officer Raymond Woo reported a mix of option exercises, stock sales, and new equity awards. On April 1, he exercised stock options for a total of 11,112 shares of common stock at exercise prices of $2.24 and $4.70 per share, then sold the same 11,112 shares in open-market transactions at prices around $18.53–$18.58. The filing notes these trades were made under a Rule 10b5-1 trading plan. Woo also received new grants: 51,227 stock options at an exercise price of $18.50 and 30,736 restricted stock units, bringing his direct common stock holdings to 197,648 shares after the transactions.
CBLL reported proposed resale transactions under a Form 144. The filing lists securities to be sold on 04/01/2026 arising from option grants dated 07/07/2021 (1,472 shares) and 02/16/2023 (9,640 shares). The filing also records prior open-market sales by Raymond Woo: 01/02/2026 (11,112 shares for $235,228.09), 02/02/2026 (11,112 shares for $228,408.70), 03/02/2026 (11,112 shares for $202,831.12), and 02/23/2026 (705 shares for $13,955.12). The broker on the notice is Fidelity Brokerage Services LLC.
Ceribell, Inc. President and CEO Chao Xingjuan reported exercising stock options to acquire a total of 55,628 shares of common stock. She exercised options for 36,628 shares at an exercise price of $2.24 per share and 19,000 shares at $3.65 per share.
After these transactions, she holds 766,792 shares of common stock directly. An additional 369,088 shares are held indirectly by the ACP 2021 Trust, where she is a co-trustee and may be deemed to share beneficial ownership, while disclaiming beneficial ownership except to the extent of her pecuniary interest.
Ceribell, Inc. Senior VP, Finance and PAO David Foehr exercised stock options and sold shares in the company. On March 3, 2026, he exercised options for 3,403 and 1,157 shares of common stock at $4.70 per share and then sold the same totals, 4,560 shares of common stock, at $17.80 per share in open-market transactions. After these trades, he directly held 17,550 shares of Ceribell common stock. The sales were made under a pre-arranged Rule 10b5-1 trading plan adopted on September 4, 2025, and the underlying options vest over time through monthly installments after an initial 25% vesting on May 31, 2023.
Ceribell, Inc. director Rebecca B. Robertson reported an open-market sale of 827 shares of common stock at $17.80 per share. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan, and she now holds 18,749 shares directly.